| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/21/2005 | CA2544611A1 Method of treating airway diseases with beta-adrenergic inverse agonists |
| 04/21/2005 | CA2542295A1 Method |
| 04/21/2005 | CA2542099A1 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 04/21/2005 | CA2542096A1 Thiophene and benzothiophene hydroxamic acid derivatives |
| 04/21/2005 | CA2542034A1 Thiadiazoline derivatives |
| 04/21/2005 | CA2542031A1 Pyrimidine derivatives for treatment of hyperproliferative disorders |
| 04/21/2005 | CA2542008A1 Substituted tricyclic heterocycles and their uses |
| 04/21/2005 | CA2541831A1 1-'2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists |
| 04/21/2005 | CA2541815A1 Methods and means for modulating lipid metabolism |
| 04/21/2005 | CA2541771A1 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function |
| 04/21/2005 | CA2541667A1 Substituted pyrazinone compounds for the treatment of inflammation |
| 04/21/2005 | CA2541590A1 Treatment of diseases associated with the egr-1 enhancer element |
| 04/21/2005 | CA2541584A1 Composition for promoting collagen production comprising a purine nucleic acid-related substance and a pyrimidine nucleic acid-related substance |
| 04/21/2005 | CA2541582A1 Indoles and azaindoles as antiviral agents |
| 04/21/2005 | CA2541548A1 Treatment of diseases involving erbb2 kinase overexpression |
| 04/21/2005 | CA2541438A1 The modulation of hyaluronan synthesis and degradation in the treatment of disease |
| 04/21/2005 | CA2541382A1 A solid dosage form comprising a fibrate and a statin |
| 04/21/2005 | CA2541371A1 Extended release formulations of opioids and method of use thereof |
| 04/21/2005 | CA2541162A1 Fused lactam compounds |
| 04/21/2005 | CA2541126A1 Animal feed composition |
| 04/21/2005 | CA2541060A1 Compositions and methods for treatment of muscle pain and muscle wasting |
| 04/21/2005 | CA2540978A1 Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| 04/21/2005 | CA2540977A1 Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| 04/21/2005 | CA2540868A1 Pyrrolidinyl urea derivatives as angiogenesis inhibitors |
| 04/21/2005 | CA2540867A1 Process for the preparation of n-amino substituted heterocyclic compounds |
| 04/21/2005 | CA2540849A1 Plant seed extract composition and process for producing the same |
| 04/21/2005 | CA2540838A1 Process for the synchronization of ovulation for timed breeding without heat detection |
| 04/21/2005 | CA2540586A1 Treatment of a condition in a mammal with administration of aminosugar and uses thereof |
| 04/21/2005 | CA2540307A1 Subtituted fullerene compositions and their use as antioxydants |
| 04/21/2005 | CA2540202A1 Sustained release l-arginine formulations and methods of manufacture and use |
| 04/21/2005 | CA2540147A1 Colon cleansing composition and method |
| 04/21/2005 | CA2540051A1 Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase the life expectancy of human beings |
| 04/21/2005 | CA2540042A1 Aerosol formulation comprising formoterol in suspension |
| 04/21/2005 | CA2540038A1 Aerosol formulations comprising formoterol fumarate dihydrate, a propellant,ethanol and optionally a steroid,where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight |
| 04/21/2005 | CA2539882A1 Substituted isoquinolinones |
| 04/21/2005 | CA2539878A1 Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics |
| 04/21/2005 | CA2539872A1 Compositions for conjugated estrogens and associated methods |
| 04/21/2005 | CA2539868A1 A method of healing skin wounds in mammals and a composition therefor |
| 04/21/2005 | CA2539801A1 Therapeutic formulations |
| 04/21/2005 | CA2539587A1 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics |
| 04/21/2005 | CA2539572A1 1-(quinoline amino) and 1-(isoquinoline amino)-substituted pentan-2-ols, method for their production and their use as anti-inflammatories |
| 04/21/2005 | CA2539568A1 Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
| 04/21/2005 | CA2539502A1 (3r,4r)-trans-3,4-diarylchroman derivatives with estrogenic activity |
| 04/21/2005 | CA2539449A1 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir) |
| 04/21/2005 | CA2538445A1 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 04/21/2005 | CA2538430A1 Novel methods for identifying improved, non-sedating alpha-2 agonists |
| 04/21/2005 | CA2538403A1 Compositions and methods for treatment of cancer |
| 04/21/2005 | CA2538362A1 Water dispersible film |
| 04/21/2005 | CA2538106A1 Antimicrobial compositions comprising modified catechins and methods of use therein |
| 04/21/2005 | CA2538099A1 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin |
| 04/21/2005 | CA2538093A1 Porifera-based therapeutic compositions for treating and preventing skin diseases |
| 04/21/2005 | CA2537473A1 Cytokine involved in epithelial-mesenchymal transition |
| 04/21/2005 | CA2535930A1 Inhibitors of cathepsin s |
| 04/21/2005 | CA2533886A1 Methods of reducing risk of infection from pathogens |
| 04/21/2005 | CA2528100A1 Polymorphic forms of ziprasidone hcl and processes for their preparation |
| 04/20/2005 | EP1524273A1 Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(IV) salts and derivatives and their use for the preparation of pharmaceutical active agents |
| 04/20/2005 | EP1524270A1 Sulfur-containing proanthocyanidin oligomer composition and process for producing the same |
| 04/20/2005 | EP1524269A1 Use of 8-Prenylnaringenin for hormone replacement therapy |
| 04/20/2005 | EP1524267A1 Substituted benzylaminoalkylene heterocycles |
| 04/20/2005 | EP1524266A1 Pharmaceutical composition |
| 04/20/2005 | EP1524263A1 prodrugs containing cycloalkene derivatives |
| 04/20/2005 | EP1523998A2 Antimicrobial adhesive sheet and antimicrobial method using the same |
| 04/20/2005 | EP1523994A1 Medicinal composition for regulating release and process for producing the same |
| 04/20/2005 | EP1523985A1 Strontium agent and method for treating cancer |
| 04/20/2005 | EP1523983A1 Pharmaceutical composition comprising fenofibrate and process for its preparation |
| 04/20/2005 | EP1523982A2 Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
| 04/20/2005 | EP1523981A1 Extended release formulations of venlafaxine |
| 04/20/2005 | EP1523980A2 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 04/20/2005 | EP1523979A1 Extended release pharmaceutical dosage form |
| 04/20/2005 | EP1523976A2 Pharmaceutical formulations of salmeterol |
| 04/20/2005 | EP1523975A2 Pressurised metered dose inhalers (MDI) |
| 04/20/2005 | EP1523887A2 Synergistic microbicidal combinations |
| 04/20/2005 | EP1523577A2 Method for diagnosis of intestinal-type gastric tumors |
| 04/20/2005 | EP1523571A2 Sgk and nedd used as diagnostic and therapeutic targets |
| 04/20/2005 | EP1523556A1 Methods of treating conditions associated with an edg-1 receptor |
| 04/20/2005 | EP1523489A2 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 04/20/2005 | EP1523488A1 Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof |
| 04/20/2005 | EP1523486A2 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| 04/20/2005 | EP1523485A1 3-furanyl analogs of toxoflavine as kinase inhibitors |
| 04/20/2005 | EP1523484A2 3-phenyl analogs of toxoflavine as kinase inhibitors |
| 04/20/2005 | EP1523480A2 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 04/20/2005 | EP1523476A2 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors |
| 04/20/2005 | EP1523475A1 Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| 04/20/2005 | EP1523473A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 04/20/2005 | EP1523471A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 04/20/2005 | EP1523470A1 Novel compounds as histone deacetylase inhibitors |
| 04/20/2005 | EP1523469A1 Cinnamide derivatives |
| 04/20/2005 | EP1523465A1 An hydroxytyrosol-rich composition from olive vegetation water and method of use thereof |
| 04/20/2005 | EP1523372A2 Ghrelin-carrier conjugates |
| 04/20/2005 | EP1523345A1 Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis |
| 04/20/2005 | EP1523344A1 Stents containing sgc activators |
| 04/20/2005 | EP1523335A2 Injectable depot formulation comprising crystals of iloperidone |
| 04/20/2005 | EP1523328A2 Methods and compositions for inhibiting hiv replication |
| 04/20/2005 | EP1523325A2 Methods and compositions for treating polycystic ovary syndrome |
| 04/20/2005 | EP1523321A1 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 04/20/2005 | EP1523318A2 Treatment of human multiple myeloma by curcumin |
| 04/20/2005 | EP1523317A2 Control of protozoa and protonzoan cysts that harbor legionella |
| 04/20/2005 | EP1523316A2 Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
| 04/20/2005 | EP1523313A1 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4- 1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| 04/20/2005 | EP1523312A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |